Abstract | AIMS: METHODS: Data from 2641 patients initiated therapy with either metformin, sulfonylurea, DPP-inhibitors or GLP-1 with baseline BMI >30 were retrospectively analyzed (Disease Analyzer Germany: 11/2008-10/2012). Comparison was performed for the weight change after 1 year of therapy compared with the last value prior to therapy. Differences between SU, DPP-4, GLP-1 versus metformin were estimated using regression model adjusted for age, gender, health insurance status, defined co-diagnoses and body weight at baseline. RESULTS: In absolute values, metformin patients lost an average of 2.6 kg, subjects treated with SU gained 0.3 kg, body weight in the DPP-4 group decreased by 1.8 kg and GLP-1 patients lost 3.3 kg in body weight after 1 year. After adjustment for other variables, comparisons with metformin revealed the following results: SU +3.4 kg (p < 0.001), DPP-4 +1.0 kg (p = 0.003) and GLP-1 -0.4 kg (p = 0.589). CONCLUSION: Our study showed that GLP-1 treatment was comparable to metformin regarding the weight reduction, while sulfonylurea and DPP-4 are inferior in this regard.
|
Authors | Karel Kostev, Juliana Rex, Timo Rockel, Christina Heilmaier |
Journal | Primary care diabetes
(Prim Care Diabetes)
Vol. 9
Issue 1
Pg. 74-7
(Feb 2015)
ISSN: 1878-0210 [Electronic] England |
PMID | 24815575
(Publication Type: Comparative Study, Journal Article)
|
Copyright | Copyright © 2014 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved. |
Chemical References |
- Dipeptidyl-Peptidase IV Inhibitors
- Hypoglycemic Agents
- Sulfonylurea Compounds
- Glucagon-Like Peptide 1
|
Topics |
- Aged
- Databases, Factual
- Diabetes Mellitus, Type 2
(drug therapy)
- Dipeptidyl-Peptidase IV Inhibitors
(therapeutic use)
- Female
- Glucagon-Like Peptide 1
(therapeutic use)
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Male
- Middle Aged
- Retrospective Studies
- Sulfonylurea Compounds
(therapeutic use)
- Time Factors
- Treatment Outcome
- Weight Loss
(drug effects)
|